Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics
CRDF Price/Volume Stats
| Current price | $4.18 | 52-week high | $6.42 |
| Prev. close | $4.17 | 52-week low | $0.94 |
| Day low | $4.09 | Volume | 343,200 |
| Day high | $4.38 | Avg. volume | 1,490,625 |
| 50-day MA | $4.15 | Dividend yield | N/A |
| 200-day MA | $2.15 | Market Cap | 186.75M |
CRDF Stock Price Chart Interactive Chart >
Cardiff Oncology, Inc. (CRDF) Company Bio
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CRDF News From Around the Web
Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare ConferenceCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023. |
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. |
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning! |
CRDF Price Returns
| 1-mo | -22.45% |
| 3-mo | 180.54% |
| 6-mo | 298.10% |
| 1-year | 171.43% |
| 3-year | -55.34% |
| 5-year | 22.94% |
| YTD | 182.43% |
| 2023 | 5.71% |
| 2022 | -76.71% |
| 2021 | -66.59% |
| 2020 | 1,350.81% |
| 2019 | -60.63% |
Loading social stream, please wait...